Related Experiment Video
Updated: May 18, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MUC1 immunotherapy is here to stay
Takashi Kimura1, Olivera J Finn
1University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA 15261 , USA.
Expert Opinion on Biological Therapy
|September 25, 2012
Summary
Cancer vaccines harnessing the immune system show promise. Targeting the MUC1 tumor antigen, a key immunotherapy target, has shown encouraging results in clinical trials for advanced cancers.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Vaccine success in reducing cancer incidence (HBV, HPV) highlights immune system potential.
- While infectious causes are unknown for most cancers, tumor antigens are identified as vaccine targets.
Purpose of the Study:
- To review two decades of research on the MUC1 tumor antigen as an immunotherapy reagent.
- To examine the impact of anti-MUC1 immunity on tumor development and prognosis.
- To analyze immunotherapy trials targeting MUC1, including vaccines, antibody, and T-cell therapies.
Main Methods:
- Review of accumulated knowledge on MUC1 over two decades.
- Examination of evidence linking anti-MUC1 immunity to tumor progression and patient outcomes.
- Analysis of clinical trial data from immunotherapies targeting MUC1.
Main Results:
- Over 1200 patients have participated in MUC1-targeted immunotherapy trials.
- Encouraging results observed, especially in less immunosuppressed patients with advanced cancer.
- Spontaneous anti-MUC1 immune responses correlate with better prognosis and reduced cancer risk.
Conclusions:
- MUC1 is abnormally expressed in over 80% of human cancers, making it a significant therapeutic target.
- Targeting MUC1 immunotherapy could potentially benefit over a million patients annually in the USA.
- Further research into MUC1-targeted immunotherapies holds significant promise for cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
01:25Mucosal Barrier of the Stomach
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...